ReviewNature reviews. Urology2013
Active surveillance of small renal masses.
Review in Nature reviews. Urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 108 citations in OpenAlex.
- Ultrasound-guided percutaneous core biopsy of renal sinus masses: diagnostic yield, safety, and clinical impact.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Urology on a changing planet: links between climate change and urological disease.Nature reviews. Urology · 2025Review
- Prognostic outcomes of surgical modalities and predictive factors for distant metastases in T1a renal cell carcinoma: a SEER database analysis.Translational andrology and urology · 2025Article
- Rate of benign histology after resection of suspected renal cell carcinoma: multicenter comparison between Korea and the United States.BMC cancer · 2024Article
- The national utilization of nonoperative management for small renal masses over 10 years.JNCI cancer spectrum · 2023Article
- The value of sestamibi single-photon emission computed tomography/computed tomography in differentiating and staging renal cell carcinomas: A systematic review.Current urology · 2022Review
- Angioprevention of Urologic Cancers by Plant-Derived Foods.Pharmaceutics · 2022Review
- Integrative Analysis of Peripheral Blood Indices for the Renal Sinus Invasion Prediction of T1 Renal Cell Carcinoma: An Ensemble Study Using Machine Learning-Assisted Decision-Support Models.Cancer management and research · 2022Article
- Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers.Computational and structural biotechnology journal · 2019Article
- [Watchful waiting and active surveillance of small renal masses].Der Urologe. Ausg. A · 2018Article
- Article
- Kidney Cancer Incidence in California: End of the Trend?Kidney cancer (Clifton, Va.) · 2017Article
- FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ≤7-cm clear cell renal cell carcinomas.Oncotarget · 2016Article
- Risk of metastasis for T1a renal cell carcinoma.World journal of urology · 2016Article
- Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size.Urologic oncology · 2015Article
- Percutaneous biopsy for risk stratification of renal masses.Therapeutic advances in urology · 2015Review
- Indications for biopsy and the current status of focal therapy for renal tumours.Translational andrology and urology · 2015Review
- Stereotactic Ablative Radiotherapy for the Treatment of Clinically Localized Renal Cell Carcinoma.Journal of oncology · 2015Review
- Landmarks in the diagnosis and treatment of renal cell carcinoma.Nature reviews. Urology · 2014Review
- Heterogeneity and renal mass biopsy: a review of its role and reliability.Cancer biology & medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased diagnosis of small renal masses (SRMs) poses the challenge of how best to manage patients with tumours that are not likely to progress and cause death during their lifetime. Concerns regarding overdiagnosis and overtreatment of patients with low-risk or indolent disease has led to the introduction of active surveillance as an alternative to immediate intervention in select candidates. However, differentiating between benign or low-grade lesions and high-grade aggressive phenotypes is difficult. Renal biopsy, radiographic assessment, and clinical nomograms have been used before surgery to evaluate the probability of whether an SRM will exhibit characteristics of an aggressive cancer. SRM growth trends have been studied over periods of observation but no characteristics have been found to correlate with aggressive growth kinetics. Stratification of patients with SRMs according to risk status is crucial when considering whether active surveillance might be an appropriate treatment option. Factors that should be taken into account include comorbidities, a history of malignancy, pre-existing chronic kidney disease, life expectancy and patient preference. Standardized active surveillance protocols are currently lacking, and clinical trials designed to randomize patients with SRMs to receive either active surveillance or immediate treatment are sorely needed to address the existing evidence gap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.